regardless of promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from PBMs. These companies are often building limitations to coverage, like steep cost restrictions and approval processes that limit user opportunity. Market believe that thes